Navelbine 20mg and 30mg Soft Capsules

  • Name:

    Navelbine 20mg and 30mg Soft Capsules

  • Company:
    info
  • Active Ingredients:

    Vinorelbine tartrate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/05/20

files-icon(Click to Download)

XPIL

Pierre Fabre Limited

Pierre Fabre Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Braftovi 50 mg hard capsules Active Ingredients Encorafenib
Medicine Name Braftovi 75 mg hard capsules Active Ingredients Encorafenib
Medicine Name Busilvex 6 mg/ml concentrate for solution for infusion Active Ingredients Busulfan
Medicine Name Javlor 25 mg/ml concentrate for solution for infusion Active Ingredients Vinflunine Ditartrate
Medicine Name Mektovi 15 mg film-coated tablets Active Ingredients Binimetinib
Medicine Name Navelbine 20mg and 30mg Soft Capsules Active Ingredients Vinorelbine tartrate
Medicine Name Navelbine 20mg Soft Capsule Active Ingredients Vinorelbine tartrate
Medicine Name Navelbine 30mg Soft Capsule Active Ingredients Vinorelbine tartrate
Medicine Name Nerlynx 40 mg film-coated tablets Active Ingredients Neratinib Maleate
1 - 0 of 9 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 May 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Free text change information supplied by the pharmaceutical company

Updated PIL following aType II C.I.4 worksharing variation; Harmonisation of Section 4 of the PIL of Navelbine Soft Capsules in all European Countries.

Updated on 21 May 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Free text change information supplied by the pharmaceutical company

Updated PIL following a Type II C.I.4 worksharing variation; Harmonisation of the Section 4 of the PIL of Navelbine Soft Capsules in all European Countries.

Updated on 21 May 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Free text change information supplied by the pharmaceutical company

Updated PIL following a Type II C.I.4 worksharing variation; Harmonisation of Section 4 of the SmPC of Navelbine Soft Capsules in all European Countries.

Updated on 2 October 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

The Marketing Authorisation (MA) has been transferred to an EU entity as a result of Brexit, see section 6.

The Product Authorisation (PA) number has been updated to reflect the new MA Holder.

Updated on 8 February 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 February 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 12 July 2016 PIL

Reasons for updating

  • Change to date of revision

Updated on 5 February 2016 PIL

Reasons for updating

  • Change to side-effects
  • PIL retired pending re-submission

Updated on 16 January 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Addition of information on reporting a side effect.

Updated on 30 December 2011 PIL

Reasons for updating

  • Change due to harmonisation of PIL

Updated on 12 August 2011 PIL

Reasons for updating

  • Change due to harmonisation of PIL

Updated on 3 August 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 11 December 2009 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 3 December 2007 PIL

Reasons for updating

  • New PIL for new product